Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Cabozantinib in Advanced Sarcomas
NCT05182164Phase 2Recruiting
- Sponsor
- Institut Bergonié
- Start
- Apr 2022
- Primary completion
- Dec 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, cabozantinib in undifferentiated pleomorphic sarcoma (UPS), osteosarcoma (OS), Ewing sarcoma, sponsored by Institut Bergonié. Started Apr 2022; status: recruiting.
02
Drugs
pembrolizumabcabozantinib
03
Conditions
undifferentiated pleomorphic sarcoma (UPS)osteosarcoma (OS)Ewing sarcoma
Beyond the preview
Go deeper on NCT05182164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05182164.